The company is launching new self-pay pricing options, expanded savings programs, and partnerships with telehealth and retail providers. all while its obesity portfolio gains momentum under the FDA’s National Priority Voucher program.
In a special promotion, Novo Nordisk’s Wegovy (semaglutide) injection and Ozempic are being sold for $199 per month to new self-pay patients until March 31, 2026. This deal—serving as an introductory offer—is valid for the patient’s initial two months of therapy, and can be applied toward the two lowest doses (the 0.25 mg and 0.5 mg varieties) of either Wegovy or Ozempic.1
The fee will adjust to the regular monthly self-pay price of $349 (which has decreased by $150) following the limited-time promo.
After a recent agreement with the Trump administration to broaden access to obesity and chronic-disease medicines, while also decreasing direct-to-patient prices in 2026, Novo Nordisk is delivering those reduced prices to consumers several months ahead of schedule.
"As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them," commented Dave Moore, Novo Nordisk’s EVP of US operations. "The US healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines. Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay. It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the Administration to lower costs for people living with chronic diseases like obesity and type 2 diabetes."
There are various ways that patients can take advantage of these self-pay offers:
When it comes to WeightWatchers, it was recently revealed that the company intends to offer Novo Nordisk’s pill version of Wegovy—if it makes its US debut next year following FDA approval.2
However, a Novo Nordisk spokesperson did clarify with Pharmaceutical Commerce via email that “oral semaglutide for chronic obesity is under FDA review and not yet approved. If and when it is approved, we will communicate the ways in which we will make it accessible and affordable in line with our mission to serve patients in the US with obesity.”
• $199 intro offer: New self-pay patients can access Wegovy or Ozempic for $199/month for their first two months through March 31, 2026.
• Applies to starter doses: The promotion covers the 0.25 mg and 0.5 mg doses of either medication.
• New standard price is $349: After the intro period, the self-pay price adjusts to $349/month, reflecting a $150 decrease.
This is occurring amid a time when the FDA added Wegovy to the Commissioner’s National Priority Voucher (CNPV) program, growing the initiative to a total of 15 products that tackle public health and national security priorities.2
Per this pilot CNPV program, qualifying sponsors can obtain a voucher that allows the FDA to complete its review in as little as one to two months, compared to the standard 10-12-month review window that normally follows the final submission process.
“National priority vouchers are granted to a select group of products where the company has agreed to increase affordability, domesticate manufacturing as a national security issue, or address an unmet public health need,” FDA Commissioner Marty Makary, MD, MPH, said in a press release.2 “We are pioneering new ways of bringing these cures and meaningful treatments to the market faster.”
For patients with commercial insurance who are eligible, Novo Nordisk still offers savings programs that can reduce monthly costs to as low as $0 for Wegovy and $25 for Ozempic.
References
1. Novo Nordisk Launches Introductory Self-Pay Offer for Wegovy and Ozempic for $199 per Month. Novo Nordisk. November 17, 2025. Accessed November 18, 2025.
2. Saraceno N. WeightWatchers to Offer Novo Nordisk’s Oral Wegovy, if Approved Next Year. Pharmaceutical Commerce. November 13, 2025. Accessed November 18, 2025.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
